a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .

An edge is a relationship stated by a source (CIViC evidence item, ChEMBL indication or mechanism, openFDA approval) and kept with its native evidence level, direction and cancer context — CancerIndex never infers, merges or re-scales it. Rows marked are counts and measurements read from registries (ClinicalTrials.gov conditions and interventions, GDC/cBioPortal cohort frequencies ≥ 5 % with ≥ 20 cases affected, regulatory approval records): they say how often two entities co-occur in a registry, not that a source asserted a biological or clinical link. Trials are rolled up over the cancer and its descendants; approvals list authority, jurisdiction and date as published.